

June 1, 2022

SymBio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director,  
 President and Chief Executive Officer

**Completion of Payment for the Issuance of New Shares and  
 the 58th Stock Acquisition Rights through Third-party Allotment**

TOKYO, Japan, June 1, 2022—SymBio Pharmaceuticals Limited (TSE: 4582) (“SymBio” or the “Company”) today announced that CVI Investments, Inc. (the “Allottee”) has completed payment to the Company for the issuance of new shares (the “New Shares”) and the 58th stock acquisition rights (the “Stock Acquisition Rights”) through a third-party allotment pursuant to the transaction approved by the Company’s board of directors on May 16, 2022. For further details, please refer to the Company’s press release of May 16, 2022 titled “Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment.”

1. Issuance of New Shares

(1) Date of allotment	June 1, 2022
(2) Number of shares to be issued	1,000,000 common shares
(3) Issue price	¥662 per share
(4) Amount of funding	¥662,000,000
(5) Increase of capital stock	¥331,000,000 (¥331 per share)
(6) Increase of legal capital surplus	¥331,000,000 (¥331 per share)
(7) Subscription method	Third-party allotment
(8) Allottee	CVI Investments, Inc.

2. Issuance of the Stock Acquisition Rights

(1) Date of allotment	June 1, 2022
(2) Number of stock acquisition rights	20,000 units (100 shares per unit)
(3) Issue price	Total of ¥13,760,000 (¥688 per unit)
(4) Number of dilutive shares from the issuance	2,000,000 shares
(5) Amount of funding (value of property to be contributed in exercising the Stock Acquisition Rights)	¥1,583,760,000 (Note)
(6) Exercise price and conditions for revising the exercise price	Exercise price of ¥785 The exercise price shall not be revised.

(7) Exercise period	From June 2, 2022 to June 1, 2027
(8) Method for subscription or allotment	Third-party allotment
(9) Allottee	CVI Investments, Inc.
(10) Other terms	<p>The Purchase Agreement stipulates the following.</p> <p>(1) The issuance of the Stock Acquisition Rights allotted to the aforementioned Allottee is subject to conditions that include the following:</p> <p>1) The representations and warranties made by Symbio in the Purchase Agreement are accurate in material respects, and the Company has fulfilled its important pledges.</p> <p>2) No injunction, etc., has been made against the issuance of the Stock Acquisition Rights.</p> <p>3) Symbio’s shares have not been delisted.</p> <p>4) No events have occurred that could have a material adverse impact on Symbio.</p> <p>5) Symbio has not omitted to inform the Allottee of undisclosed material facts related to the Company.</p> <p>(2) The transfer of the Stock Acquisition Rights (excluding transfers to Bank of America, J.P. Morgan, Goldman Sachs &amp; Co., and their affiliates from the perspective of reducing management costs for the Allottee) shall require the approval of Symbio’s board of directors. If the Stock Acquisition Rights are transferred, the rights and obligations of the Allottee will be assumed by the transferee.</p> <p>In addition, as outlined in “3. Overview of the Funding Method and Reason for Selection, (1) Overview of the Funding Method” and in “7. Reasons for Having Chosen the Allottee, etc., (5) Lock-up Period, etc.” of the press release regarding this issuance published on May 16, 2022, the Purchase Agreement sets out other conditions including with respect to purchase of the Stock Acquisition Rights and a lock-up period for the issuance of the new shares. Please refer to the Company’s press release regarding this issuance published on May 16, 2022.</p>

(Note) If the Stock Acquisition Rights are not exercised during the exercise period, and Symbio cancels the Stock Acquisition Rights it has acquired, the amount of funding may be lower than the amount shown.

### 3. Changes in the number of shares issued and the amount of capital stock as a result of the issuance of the Shares

	Total number of shares issued	Amount of capital stock
Before the issuance of Shares (as of May 13, 2022)	38,553,931 shares	17,196,797 thousand yen
Increase due to the issuance of Shares	1,000,000 shares	331,000 thousand yen
After the issuance of Shares (Note)	39,553,931 shares	17,527,797 thousand yen

(Note) The total number of shares issued and the amount of capital stock after the issuance of Shares do not include the increase of shares due to the exercise of stock acquisition rights after May 16, 2022.